Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 12:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 2,318 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Multiple Myeloma Clear all
Completed Phase 3 Interventional

Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00017602
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
oblimersen sodium, dexamethasone
Biological · Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Berkeley Heights, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Phase 1Phase 2 Interventional

Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

NCT00499577
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
CMV pp65 peptide, hTERT I540/R572Y/D988Y multipeptide vaccine, pneumococcal polyvalent vaccine, survivin Sur1M2 peptide vaccine
Biological
Lead sponsor
University of Maryland Greenebaum Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Phase 1 Interventional

Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

NCT00301951
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, sargramostim, busulfan, fludarabine phosphate, mycophenolate mofetil, tacrolimus, umbilical cord blood transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Multiple Myeloma

NCT00003493
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
dexamethasone, pegylated liposomal doxorubicin hydrochloride, vincristine sulfate
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 28, 2026, 12:23 AM EDT
Active, not recruiting Early Phase 1 Interventional

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

NCT05560399
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Iberdomide, Elotuzumab, Dexamethasone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Results available

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

NCT01478581
View directory record Official record
Conditions
Multiple Myeloma
Interventions
PCI-32765, Dexamethasone
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
11
States / cities
La Jolla, California • Baltimore, Maryland • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Results available

Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib

NCT01775553
View directory record Official record
Conditions
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Carfilzomib
Drug
Lead sponsor
Ajai Chari
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 28, 2026, 12:23 AM EDT
Not listed Phase 1Phase 2 Interventional

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

NCT01522872
View directory record Official record
Conditions
Multiple Myeloma
Interventions
TH-302, TH-302 and Dexamethasone, TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib, TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
10
States / cities
Monterey, California • Tampa, Florida • Scarborough, Maine + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 28, 2026, 12:23 AM EDT
Withdrawn Phase 2 Interventional

2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

NCT03003728
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Melphalan, Autologous Stem Cell Transplant (ASCT), Expanded Natural Killer (ENK) Cells, ALT-803
Drug · Procedure · Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 28, 2026, 12:23 AM EDT
Recruiting Not applicable Interventional

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

NCT07390071
View directory record Official record
Conditions
Lymphoma, Myeloma, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions
Home Automated Telemanagement (HAT) Patient Unit
Device
Lead sponsor
University of Utah
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Phase 2 Interventional

Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma

NCT00067639
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pegfilgrastim (Neulasta), Apheresis
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Results available

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

NCT02064387
View directory record Official record
Conditions
Multiple Myeloma
Interventions
GSK2857916
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Phase 2 Interventional

Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis

NCT00075621
View directory record Official record
Conditions
Multiple Myeloma
Interventions
filgrastim, melphalan, autologous peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 28, 2026, 12:23 AM EDT
Recruiting Phase 1 Interventional

Personalized Autologous Transplant for Multiple Myeloma

NCT04483206
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Melphalan, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 28, 2026, 12:23 AM EDT
Active, not recruiting Phase 1 Interventional

Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

NCT03672318
View directory record Official record
Conditions
Multiple Myeloma, Immune System Diseases
Interventions
CAR138 T Cells
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2039
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 28, 2026, 12:23 AM EDT
Not listed Phase 2 Interventional

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

NCT03570983
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Allopurinol, Carmustine, Etoposide, Cytarabine, Melphalan
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Not applicable Interventional Results available

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

NCT01383759
View directory record Official record
Conditions
Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD), Monoclonal Immunoglobulin Deposition Disease (MIDD), Amyloidosis
Interventions
Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 28, 2026, 12:23 AM EDT
Recruiting Phase 3 Interventional

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT07518186
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JNJ-79635322, Teclistamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Springdale, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Phase 1 Interventional

Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM

NCT01114282
View directory record Official record
Conditions
Multiple Myeloma
Interventions
velcade, Pralatrexate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 28, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 28, 2026, 12:23 AM EDT
Terminated Phase 1 Interventional

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

NCT00460460
View directory record Official record
Conditions
Lymphoma
Interventions
AZD4877
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
2
States / cities
Buffalo, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Oct 28, 2026, 12:23 AM EDT
Terminated Phase 1 Interventional

Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma

NCT05908396
View directory record Official record
Conditions
Multiple Myeloma
Interventions
IGM-2644
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Duarte, California • Denver, Colorado • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 28, 2026, 12:23 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

NCT01177683
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bendamustine, Doxorubicin, Bortezomib, Filgrastim
Drug
Lead sponsor
Sherif Farag, MB, BS
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
7
States / cities
Indianapolis, Indiana • Lafayette, Indiana • Wyoming, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 28, 2026, 12:23 AM EDT
Terminated Phase 1 Interventional

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

NCT06304636
View directory record Official record
Conditions
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions
Descartes-15
Drug
Lead sponsor
Cartesian Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 28, 2026, 12:23 AM EDT